Assistant Professor  


                                           PHD:           2012, Ruprecht-Karls-Universität Heidelberg

Scientific interests

Our group focuses on understanding the molecular and cellular mechanisms that mediate resistance to anti-cancer therapies in cancer. Using state-of-the-art mouse models of cancer, as well as quantitative molecular and cellular approaches, we are interested in dissecting the microenvironmental cues that orchestrate specific tumour responses and metastasis formation.

Recent publications

  • Martinez-Usatorre A, Kadioglu E, Cianciaruso C, Guichard A, Torchia B, Nassiri S, Keklikoglou I, Schmittnaegel M, Ries CH, Meylan E, and De Palma M (2021). Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. Science Translational Medicine, Aug 11;13(606):eabd1616.
  • Keklikoglou I, Cianciaruso C, Guc E, Squadrito ML, Spring LM, Tazzyman S, Lambein L, Poissonier A, Ferraro GB, Baer C, Cassara A, Guichard A, Iruela-Arispe ML, Lewis CE, Coussens LM, Bardia A, Jain RK, Pollard JW, and De Palma M (2019). Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nature Cell Biology, 21(2):190-202. Highlight: Nat Rev Cancer 2019 (doi: 10.1038/s41568-019-0111-2).  Highlight: F1000Prime (
  • Keklikoglou I, Kadioglu E, Bissinger S, Langlois B, Bellotti A, Orend G, Ries CH, and De Palma M (2018). Periostin limits tumor response to VEGFA inhibition. Cell Reports, Volume 22, Issue 10, 2530 – 2540. Featured Cover Article
  • Hughes R, Qian BZ, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Clemons M, Gonzalez-Angulo AM, Joyce JA, De Palma M, Pollard JW, and Lewis CE (2015). Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Research, 75(17):3479-91
  • Keklikoglou I, Hosaka K, Bender C, Bott A, Koerner C, Mitra D, Will R, Woerner A, Muenstermann E, Wilhelm H, Cao Y, and Wiemann S (2015). MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene, 34(37):4867-78.